News

Applying complement therapeutics to rare diseases

October 2, 2015

Highlights:
  • It is estimated that about 350 million people worldwide suffer from rare diseases.
  • The launch of effective treatments for rare diseases is challenging when there is a low disease prevalence and limited scientific insights into the disease mechanisms
  • As a key trigger of inflammatory processes, complement has been associated with a variety of diseases and has become an attractive therapeutic target for conditions involving inflammation.
  • Clinical evidence shows the safety and efficacy of complement therapeutics
  • This review provides an overview of the candidates currently in the pharmaceutical pipeline with potential to treat orphan diseases and discusses the molecular mechanisms triggered by complement involved with the disease pathogenesis.
Author and source information

Authors: Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD.
Reference: Clinical Immunology.2015 Dec;161(2):225-240. doi:10.1016/j.clim.2015.08.009. [Epub ahead of print].
Source: www.ncbi.nlm.nih.gov

 

Comments are closed.